VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 100 filers reported holding VERONA PHARMA PLC in Q3 2023. The put-call ratio across all filers is 3.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,954,865 | -22.9% | 3,187,415 | 0.0% | 2.00% | -35.7% |
| Q2 2023 | $67,381,953 | +5.3% | 3,187,415 | 0.0% | 3.12% | +18.6% |
| Q1 2023 | $64,003,293 | -23.2% | 3,187,415 | 0.0% | 2.63% | -24.8% |
| Q4 2022 | $83,287,154 | +188.1% | 3,187,415 | +12.7% | 3.50% | +164.1% |
| Q3 2022 | $28,913,000 | – | 2,829,094 | – | 1.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |